Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | MC5R | P33032 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.51 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637536 | 1.00 | ACHE (0.64) | ACHEKMT2ASIGMAR1PKMMC4R | |
| SCHEMBL4842070 | 1.00 | ACHE (0.64) | ACHEKMT2ASIGMAR1PKMMC4R | |
| SCHEMBL4834727 | 0.91 | ACHE (0.72) | ACHEKMT2ASIGMAR1PKMMC4R | |
| Hydrochloric Acid SCHEMBL6306233 | 0.89 | ACHE (0.70) | ACHEKMT2ASIGMAR1PKMMC4R | |
| SCHEMBL14197720 | 0.82 | ACHE (0.83) | ACHEKMT2ASIGMAR1PKMMEN1 | |
| SCHEMBL30772041 | 0.82 | ACHE (0.64) | ACHEKMT2ASIGMAR1PKMMC4R | |
| SCHEMBL42501 | 0.80 | ACHE (0.58) | ACHESIGMAR1DRD4LTA4H | |
| SCHEMBL239922 | 0.80 | ACHE (0.58) | ACHESIGMAR1DRD4LTA4H | |
| SCHEMBL330609 | 0.80 | ACHE (0.58) | ACHESIGMAR1DRD4LTA4H | |
| SCHEMBL14793661 | 0.80 | ACHE (0.58) | ACHESIGMAR1DRD4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| EP-1737840-B1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-03 | — | — | US | disclosed |
| EP-1737840-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005103033-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, GOT2 | ACHE 1785/4885KMT2A 1683/4885SIGMAR1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.